New Drug Combination for Advanced Laryngeal Cancer
Part of Cancer clinical trials.
This trial tests two newer drugs (vebectotamab vedotin and pucotelimab) combined together to treat locally advanced laryngeal cancer that can be surgically removed. The goal is to see if this combination helps shrink tumors and improves outcomes before or after surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–80 years old
- Confirmed laryngeal cancer that doctors believe can be surgically removed
- At least one measurable tumor on imaging scans
- Good overall health status (ECOG score 0–2)
- Adequate blood, kidney, and liver function based on recent lab tests
- Willing to follow strict birth control requirements during and for 6–7 months after treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs (nimotuzumab and toripalimab) with chemotherapy for people with advanced tonsil cancer that can be surgically removed. The goal is to see if this approach works better than standard treatment.
This trial tests a new combination of a targeted therapy (EGFR-ADC) and an immunotherapy drug before surgery to shrink and control locally advanced throat cancer. It may help make surgery more effective and reduce the chance of recurrence.
This trial tests two new cancer-fighting drugs together to treat advanced squamous cell carcinoma (a common type of head and neck cancer) in patients who cannot tolerate or refuse platinum-based chemotherapy. The goal is to see if this combination can shrink or control the cancer.
This trial tests two drugs—becotatug vedotin and pucotenlimab—given before surgery to treat head and neck cancer that has come back in the same area. The goal is to shrink the tumor and help your body's immune system fight the cancer.
This trial tests a new drug (antibody-drug conjugate) alone or with an immunotherapy drug before surgery for head and neck cancer that can be removed. The goal is to see if this combination shrinks the tumor and improves outcomes.
This trial tests a combination of three drugs (becotatug vedotin, pucotenlimab, and cisplatin) given before surgery for head and neck cancer that has not spread far. The goal is to see if this treatment shrinks tumors and improves outcomes for patients with stage 3 or 4A disease.
Hear when a new Head & Neck Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.